GSK buys Sierra Oncology

Country

United Kingdom

GlaxoSmithKline Plc is to acquire the specialty oncology company Sierra Oncology Inc which is poised to make a regulatory submission for its lead product momelotinib in the US in the second quarter. A submission to the European Medicines agency is anticipated in the second half of 2022. Momelotinib has been developed to treat patients with myelofibrosis with anaemia. The acquisition has been valued at $1.9 billion.